阅读说明：本技术 抗cd97单克隆抗体、其可变区与恒定区序列及应用 (anti-CD 97 monoclonal antibody, variable region and constant region sequence and application thereof ) 是由 尹金龙 师冰洋 吴海刚 于 2019-10-29 设计创作，主要内容包括：本发明涉及抗CD97单克隆抗体、其可变区与恒定区序列及应用,属于生物技术领域。本发明抗CD97单克隆抗体的可变区序列包括核苷酸序列如SEQ ID NO:1所示的重链和核苷酸序列如SEQ ID NO:2所示的轻链序列。本发明所述可变区序列制备得到的抗CD97单克隆抗体能够与CD97特异性结合,可用于与CD97表达量过量、失控等有关的疾病(如脑瘤)治疗药物的制备。(The invention relates to an anti-CD 97 monoclonal antibody, a variable region and constant region sequence and application thereof, belonging to the technical field of biology. The variable region sequence of the anti-CD 97 monoclonal antibody comprises a heavy chain with a nucleotide sequence shown as SEQ ID NO. 1 and a light chain with a nucleotide sequence shown as SEQ ID NO. 2. The anti-CD 97 monoclonal antibody prepared by the variable region sequence can be specifically combined with CD97, and can be used for preparing medicaments for treating diseases (such as brain tumor) related to excessive expression quantity, uncontrolled control and the like of CD 97.)

1. The variable region sequence of the anti-CD 97 monoclonal antibody is characterized in that the variable region sequence comprises a heavy chain with a nucleotide sequence shown as SEQ ID NO. 1 and a light chain with a nucleotide sequence shown as SEQ ID NO. 2.

2. The constant region sequence of the anti-CD 97 monoclonal antibody is characterized in that the constant region sequence comprises a heavy chain with a nucleotide sequence shown as SEQ ID NO. 3 and a light chain with a nucleotide sequence shown as SEQ ID NO. 4.

3. An anti-CD 97 chimeric antigen receptor CD97-scfv based on the variable region sequence of claim 1, wherein the nucleotide sequence of CD97-scfv is shown in SEQ ID NO. 5.

4. The anti-CD 97 chimeric antigen receptor CD97-scfv of claim 3, wherein the amino acid sequence of CD97-scfv is as shown in SEQ ID NO. 6.

5. T lymphocytes comprising the anti-CD 97 chimeric antigen receptor CD97-scfv of claim 3 or 4.

6. An anti-CD 97 monoclonal antibody prepared based on the variable region sequence of claim 1 or the constant region sequence of claim 2 or the anti-CD 97 chimeric antigen receptor CD97-scfv of claim 3 or 4.

7. Use of the variable region sequence of claim 1 or the constant region sequence of claim 2 or the anti-CD 97 chimeric antigen receptor CD97-scfv of claim 3 or 4 or the T lymphocyte of claim 5 or the anti-CD 97 monoclonal antibody of claim 6 for the preparation of a medicament for the prevention and/or treatment of diseases caused by CD97 overexpression or deregulation.

8. The use of claim 7, wherein the disease comprises a brain tumor.

Technical Field

The invention relates to the technical field of biology, in particular to an anti-CD 97 monoclonal antibody with the bioactivity of specifically binding CD97, a variable region sequence and a constant region sequence thereof and application of the anti-brain tumor monoclonal antibody.

Background

Malignant brain glioma is the most common type of brain tumor in clinic, and the incidence rate of the malignant brain glioma is up to 60 percent in the brain tumor. Glioblastoma multiforme (GBM) is the most malignant type of brain glioma. The incidence of malignant brain glioma in China is 1 to 4/100. The brain Glioma Stem Cell (GSC) has the characteristics of a general stem cell, i.e. self-renewal capacity, differentiability, which plays a crucial role in invasion, drug resistance, radiation resistance, etc. of brain glioma.

CD97 is a dimeric glycoprotein containing seven transmembrane structures, has a molecular weight of 75-85 kDa, and is mainly and continuously expressed on the surfaces of macrophages/monocytes and granulocytes, but is not highly expressed in other blood cells. The biological functions of CD97 are mainly focused on rheumatoid synovium to cause inflammation (Arthritis and Rheumatism,1999,42(4): 650-. According to clinical sample analysis, in brain glioma, high expression of CD97 can remarkably enhance the invasiveness and reduce the survival rate of patients (PloS One,2013,8(4): e 62765), and shows the characteristics of the CD97 as a potential biological target of brain glioma stem cells.

An antibody is a protein molecule secreted by lymphoid B cells and consists of two identical heavy and light chains, which in turn comprise variable and constant regions. Through the specific combination of the antibody and the antigen, the purposes of neutralizing the activity of antigen molecules and finally treating diseases can be realized. However, there is currently no anti-CD 97 monoclonal antibody with therapeutic properties.

Disclosure of Invention

The invention aims to provide an anti-CD 97 monoclonal antibody, a variable region and constant region sequence and application thereof. The anti-CD 97 monoclonal antibody prepared by the variable region sequence can be specifically combined with CD97, and can be used for preparing medicaments for treating diseases (such as brain tumor) related to excessive expression quantity, uncontrolled control and the like of CD 97.

The invention provides a variable region sequence of an anti-CD 97 monoclonal antibody, which comprises a heavy chain with a nucleotide sequence shown as SEQ ID NO. 1 and a light chain with a nucleotide sequence shown as SEQ ID NO. 2.

The invention also provides a constant region sequence of the anti-CD 97 monoclonal antibody, wherein the constant region sequence comprises a heavy chain with a nucleotide sequence shown as SEQ ID NO. 3 and a light chain with a nucleotide sequence shown as SEQ ID NO. 4.

The invention also provides an anti-CD 97 chimeric antigen receptor CD97-scfv based on the variable region sequence of the technical scheme, wherein the nucleotide sequence of the CD97-scfv is shown as SEQ ID NO. 5.

Preferably, the amino acid sequence of the CD97-scfv is the sequence shown in SEQ ID NO. 6.

The invention also provides T lymphocytes containing the anti-CD 97 chimeric antigen receptor CD 97-scfv.

The invention also provides an anti-CD 97 monoclonal antibody prepared based on the variable region sequence of the technical scheme, the constant region sequence of the technical scheme or the anti-CD 97 chimeric antigen receptor CD97-scfv of the technical scheme.

The invention also provides application of the variable region sequence in the technical scheme, the constant region sequence in the technical scheme, the anti-CD 97 chimeric antigen receptor CD97-scfv in the technical scheme, the T lymphocyte in the technical scheme or the anti-CD 97 monoclonal antibody in the technical scheme in preparing a medicament for preventing and/or treating diseases caused by excessive and uncontrolled expression of CD 97.

Preferably, the disease comprises a brain tumor.

The invention provides the sequences of the constant region and the variable region of the anti-CD 97 monoclonal antibody. Compared with other traditional biological targets, the CD97 has a specific biological target closely related to the brain glioma invasiveness, and can reduce the brain glioma stem cell invasiveness, inhibit tumor proliferation and improve the survival rate of patients by inhibiting the activity of the specific biological target. The anti-CD 97 monoclonal antibody prepared by the variable region sequence can be specifically combined with CD97, and can be used for preparing medicaments for treating diseases (such as brain tumor) related to excessive expression quantity, uncontrolled control and the like of CD 97. The test result shows that the CD97 protein is interfered or silenced to remarkably inhibit the proliferation of the glioma stem cells (figure 3).

Drawings

FIG. 1 is a schematic diagram of the light chain and heavy chain plasmids of the CD97 monoclonal antibody provided by the invention; wherein, FIG. 1-1 is a schematic diagram of the light chain of the CD97 monoclonal antibody, and FIG. 1-2 is a schematic diagram of the heavy chain plasmid of the CD97 monoclonal antibody;

FIG. 2 is a graph showing the results of the binding assay between the CD97 antibody and CD97 protein; wherein, FIG. 2-1 is the result of the antigen-antibody binding force test, and FIG. 2-2 is the result of the antigen-antibody binding force test;

FIG. 3 is a graph showing that proliferation of glioma stem cell lines is significantly inhibited after silencing CD 97; wherein, fig. 3A is a graph of the efficiency of flow cytometry characterization of CD97 interfering RNA transfection into glioma stem cell line 83; FIG. 3B shows the results of Western Blotting (WB); FIG. 3C shows the results of Western Blotting (WB); FIG. 3D shows the proliferation inhibition of glioma stem cell line 83 by silencing CD 97; fig. 3E is the result of proliferation inhibition of the brain glioma stem cell line CSC2 by silencing CD 97; fig. 3F is the result of the proliferation inhibition of glioma stem cell line 528 by CD97 being silenced.

Detailed Description

The invention provides a variable region sequence of an anti-CD 97 monoclonal antibody, which comprises a heavy chain with a nucleotide sequence shown as SEQ ID NO. 1 and a light chain with a nucleotide sequence shown as SEQ ID NO. 2.

The invention also provides a constant region sequence of the anti-CD 97 monoclonal antibody, wherein the constant region sequence comprises a heavy chain with a nucleotide sequence shown as SEQ ID NO. 3 and a light chain with a nucleotide sequence shown as SEQ ID NO. 4.

The expression of the light chain and the heavy chain is preferably carried out by using a pUC plasmid, as shown in FIG. 1, and the pUC plasmid JK4-P-L (FIG. 1-1) expresses the antibody light chain fragment at the site from KnpI (1486) to Xba I (2193). The pUC plasmid JK4-P-H (FIG. 1-2) expresses antibody heavy chain fragments at sites ranging from KnpI (1486) to Xba I (2880). The invention also provides an anti-CD 97 chimeric antigen receptor CD97-scfv based on the variable region sequence in the technical scheme, wherein the nucleotide sequence of the CD97-scfv is shown in SEQ ID NO. 5:

wherein the front portion is underlined (positions 1 to 321) as the light chain variable region, non-tilted underlined (positions 322 to 375) as the linker, and tilted underlined (positions 376 to 735) as the heavy chain variable region.

In the invention, the amino acid sequence of the CD97-scfv is shown as a sequence in SEQ ID NO. 6.

Wherein the front portion is underlined (positions 1 to 107) as a light chain variable region, the non-tilted underlined (positions 108 to 125) as a linker, and the tilted and underlined (positions 126 to 245) as a heavy chain variable region.

The invention also provides T lymphocytes containing the anti-CD 97 chimeric antigen receptor CD 97-scfv.

The invention also provides an anti-CD 97 monoclonal antibody prepared based on the variable region sequence of the technical scheme, the constant region sequence of the technical scheme or the anti-CD 97 chimeric antigen receptor CD97-scfv of the technical scheme.

The invention also provides application of the variable region sequence in the technical scheme, the constant region sequence in the technical scheme, the anti-CD 97 chimeric antigen receptor CD97-scfv in the technical scheme, the T lymphocyte in the technical scheme or the anti-CD 97 monoclonal antibody in the technical scheme in preparing a medicament for preventing and/or treating diseases caused by excessive and uncontrolled expression of CD 97.

In the present invention, the disease includes a brain tumor.

The anti-CD 97 monoclonal antibody, its variable and constant region sequences and application of the present invention are further described in detail with reference to the following specific examples, which include but are not limited to the following examples.